AndhraNews.net
Home » Business News » 2014 » March » March 12, 2014

SK3 Group Completes Beta Testing of Broad Use T-Hydrocan(TM) and Prepares for Distribution to Collectives and Pharmajanes.com


March 12, 2014 - LOS ANGELES, CA

SK3 Group, Inc. (OTC Pink: SKTO) (PINKSHEETS: SKTO), doing business as Medical Greens, through its subsidiary Berkely Bio-Organic Research Laboratories, has completed beta-testing of the initial offering in its recently announced phyto-cannabinoid product line, T-Hydrocan™. T-Hydrocan™ RMC 40 contains 40 mg. of refined mixed cannabinoids which have been extracted from cannabis flowers utilizing solvents approved for food contact, refined via numerous filtration and separation processes to remove as many of the non-cannabinoid elements as possible, and pressed into a chewable tablet.

Unlike Medical Greens' non-psychoactive Dharmanol™ product line, T-Hydrocan™ RMC 40 contains fully-activated (decarboxylated) THC, producing the classic effects of medical marijuana via an orally-consumed tablet.

"While we are most excited about the possibilities of the non-psychoactive cannabinoids, the great bulk of the research, as well as the majority of the scientific knowledge of the medicinal healing effects ascribed to cannabis medicine, come from research performed on psychoactive THC. Orally-consumed doses of various types and strengths of traditional cannabis extracts have shown substantial efficacy in treating pain, anxiety, insomnia, anorexia, as well as numerous other conditions. T-Hydrocan RMC 40 tablets have been designed to benefit those seeking relief from these, and many other conditions that have been successfully treated with medicinal cannabis," said David Hoye of Berkeley Bio-Organic Research Laboratory.

Each tablet of T-Hydrocan™RMC 40 contains the following ingredients specifically:

1. Microcrystalline cellulose;
2. Magnesium stearate (vegetable source);
3. Sucrose;
4. Dextrin;
5. Natural flavorings;
6. Vitamin C as ascorbic acid (a preservative); and
7. Purified oil of cannabis / hemp containing 40 mg. of refined mixed phyto-cannabinoids.

T-Hydrocan™ RMC 40 tablets will now be packaged and made available to qualified California medical patients through the network of medicinal collectives serviced and managed by Medical Greens, as well as through the Pharmajanes.com ordering platform.

Several other products in the T-Hydrocan™ product line are being prepared for beta-testing and will soon follow the release of T-Hydrocan™ RMC 40. On the other end of the spectrum from the RMC (refined mixed cannabinoids) offering, T-Hydrocan™ Whole Plant, will contain as many of the over 400 natural medicinal elements of the cannabis/hemp plant as possible, removing only the fiber. Many patients have found the "whole plant" approach preferable to eliminating any possible medicinal element that is present in the natural plant when it is processed into an orally ingested medicine.

Following T-Hydrocan™ Whole-Plant will be T-Hydrocan™ Citrolene™ tablets, which will combine the effects of active cannabinoids with those of the natural terpene d-Limonene. This natural medicine, d-Limonene, is found in cannabis/hemp as well as in many other plants. It has relaxing, anti-anxiety, and anti-spasmodic effects, as it binds with the same receptors in the human body as does the benzodiazapines Valium and Xanax, but has been shown to be non-toxic and non-addictive.

"We are pleased to have completed this step in the development process and are looking forward to seeing T-Hydrocan™ RMC-40 tablets available through our managed collectives and Pharmajanes.com within the next 60 days," said Artemus Mayor, President of Medical Greens. "This development demonstrates our commitment to medical cannabis focused products to deliver more of what our patients want when they want it."

About SKTO
SK3 is a healthcare logistics and fulfillment consultancy doing business as Medical Greens™ and focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.

FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
SK3 Group, Inc. d.b.a Medical Greens
investors@medicalgreens.com

MarketWire

Comment on this story

Share